At-Home Sexually Transmitted Infection (STI) Testing Market Report 2026

The at-home sexually transmitted infection (STI) testing market size has grown rapidly in recent years. It will grow from $1.93 billion in 2025 to $2.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to rising prevalence of sexually transmitted infections globally, increasing awareness regarding early STI diagnosis and treatment, growing penetration of online healthcare and telemedicine services, expanding public health initiatives for HIV and STI screening, increasing consumer preference for confidential home healthcare solutions.

The at-home sexually transmitted infection (STI) testing market size is expected to see rapid growth in the next few years. It will grow to $3.55 billion by 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to growing adoption of AI-enabled digital sexual health platforms, rising demand for multiplex and rapid at-home STI diagnostic kits, increasing integration of connected and app-based testing ecosystems, expanding availability of D2C healthcare distribution channels, growing focus on preventive sexual wellness and routine screening practices. Major trends in the forecast period include increasing adoption of discreet self-collection STI screening kits for private home-based testing, growing demand for rapid turnaround sexually transmitted infection diagnostic solutions, rising preference for mail-in laboratory sexual health testing services among young adults, increasing availability of multi infection at-home sexual wellness testing panels, growing expansion of online pharmacy and direct-to-consumer sexual health testing distribution channels.

The growing awareness of sexual health is expected to propel the growth of the at-home sexually transmitted infection (STI) testing market going forward. Sexual health awareness refers to individuals’ understanding of STIs, their transmission pathways, prevention methods, and the importance of regular testing for early detection and treatment. The increasing focus on sexual health awareness is largely driven by public health campaigns and the progressive destigmatization of STI testing, which is encouraging more individuals to proactively seek information and testing options. The rising awareness of sexual health is supporting increased demand for at-home STI testing by motivating individuals to adopt confidential, convenient, and accessible testing solutions outside traditional clinical environments. For instance, in December 2025, according to the UK Health Security Agency, a UK-based government agency, infectious syphilis diagnoses rose by 1.7%, increasing from 9,375 cases in 2023 to 9,535 cases in 2024. Therefore, growing awareness of sexual health is contributing to and propelling the growth of the at-home sexually transmitted infection (STI) testing market.

Leading companies operating in the at-home STI testing market are focusing on developing advanced diagnostic technologies, such as instrument-free polymerase chain reaction platforms, to enhance detection accuracy, reduce turnaround time, and expand access to laboratory-grade results from home. Instrument-free polymerase chain reaction platforms refer to self-contained molecular diagnostic devices that enable users to collect samples at home and obtain highly accurate pathogen detection results without requiring traditional laboratory equipment, while integrating digital systems for secure result delivery and telehealth support. For example, in November 2025, Visby Medical, a US-based medical diagnostics company, launched its FDA-authorized at-home PCR test for sexually transmitted infections, which detects chlamydia, gonorrhea, and trichomoniasis, delivers results in approximately 30 minutes, operates as an instrument-free single-use device, and integrates with digital platforms to provide secure result reporting and virtual care follow-up. It is designed to support direct-to-consumer access, enhance molecular accuracy, improve testing convenience, and enable seamless telehealth-enabled treatment guidance.

In September 2025, Tia Health, a US-based women’s healthcare platform, partnered with Molecular Testing Labs to introduce the first FDA-cleared home-collected 4-plex STI test. Through this partnership, the companies seek to improve accessibility to at-home sexually transmitted infection (STI) testing by enabling users to collect samples at home and obtain accurate, laboratory-validated results. Molecular Testing Labs is a US-based diagnostic company specializing in at-home STI testing services.

Major companies operating in the at-home sexually transmitted infection (sti) testing market are Becton Dickinson and Company (BD), Laboratory Corporation of America Holdings, Randox Laboratories Ltd, LetsGetChecked, Everly Health Inc, myLAB Box LLC, Preventx Ltd, MySTDTestKits, RapidTest. co. uk Ltd, Got Lucky Labs Inc, Biopanda Reagents Ltd, Rapid Labs Ltd, Walk-In Lab LLC, Any Lab Test Now Inc, 4U Health Ltd, Quest Diagnostics Incorporated, ACON Biotech (Hangzhou) Co. Ltd, UroSure Inc, Yoxly Ltd, Genedia Co. Ltd.

North America was the largest region in the at-home sexually transmitted infection (STI) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the at-home sexually transmitted infection (STI) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the at-home sexually transmitted infection (STI) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The at-home sexually transmitted infection (STI) testing market consists of revenues earned by entities by providing services such as online consultation with healthcare professionals, digital result reporting and tracking, prescription and treatment guidance, and partner notification support. The market value includes the value of related goods sold by the service provider or included within the service offering. The at-home sexually transmitted infection (STI) testing market also includes sales of HIV self-test kits, chlamydia and gonorrhea dual test kits, syphilis rapid test kits, and HPV home screening kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.